GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (NAS:PSNL) » Definitions » Cash-to-Debt

Personalis (Personalis) Cash-to-Debt : 2.39 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Personalis Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Personalis's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Personalis could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Personalis's Cash-to-Debt or its related term are showing as below:

PSNL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.29   Med: 3.95   Max: 64.15
Current: 2.39

During the past 7 years, Personalis's highest Cash to Debt Ratio was 64.15. The lowest was 1.29. And the median was 3.95.

PSNL's Cash-to-Debt is ranked better than
58.97% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.435 vs PSNL: 2.39

Personalis Cash-to-Debt Historical Data

The historical data trend for Personalis's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Personalis Cash-to-Debt Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial 64.15 18.50 4.92 3.45 2.39

Personalis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 3.01 2.81 2.55 2.39

Competitive Comparison of Personalis's Cash-to-Debt

For the Diagnostics & Research subindustry, Personalis's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Personalis's Cash-to-Debt falls into.



Personalis Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Personalis's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Personalis's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis  (NAS:PSNL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Personalis Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Personalis's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (Personalis) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.
Executives
Richard Chen officer: Chief Scientific Officer C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Stephen Michael Moore officer: General Counsel C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Aaron Tachibana officer: Chief Financial Officer 400 NORTH MCCARTHY BLVD, MILPITAS CA 95035
Christopher M Hall officer: President 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Kenneth J Widder director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Lonnie Shoff director C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
John Stephen West director, officer: President and CEO C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Lightspeed Venture Partners Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Olivia Kyusuk Bloom director C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Myers Woodrow A Jr director 1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Ken Ludlum director
Arif Janmohamed other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed Ultimate General Partner Select Iv, L.l.c. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed General Partner Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025